Moving Immunotherapy Into Early-Stage Lung Cancer

被引:7
|
作者
Linehan, Anna [1 ]
Forde, Patrick M. [2 ]
机构
[1] Mater Misericordiae Univ Hosp, Dublin, Ireland
[2] Sidney Kimmel Comprehens Canc Ctr, Thorac Oncol Program, Baltimore, MD USA
来源
CANCER JOURNAL | 2020年 / 26卷 / 06期
关键词
Adjuvant; atezolizumab; immunotherapy; durvalumab; early stage; immune checkpoint blockade; lung cancer; neoadjuvant; nivolumab; NSCLC; PD-1; PD-L1; pembrolizumab; resectable; sintilimab; surgery; NEOADJUVANT CHEMOTHERAPY; OPEN-LABEL; DOCETAXEL; MULTICENTER; NIVOLUMAB; ATEZOLIZUMAB;
D O I
10.1097/PPO.0000000000000493
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Blockade of the programmed cell death 1 immune inhibitory pathway has revolutionized the treatment of advanced non-small cell lung cancer and led to significant improvements in overall survival. In contrast, early-stage surgically resectable lung cancer has had few treatment advances in many years and continues to be associated with a high risk of relapse despite apparent curative resection. In this review, we discuss the many ongoing efforts to incorporate programmed cell death 1 pathway blockade into the treatment paradigm for surgically resectable lung cancer both as adjuvant and neoadjuvant therapy. We review the early-phase results from neoadjuvant clinical trials, the landscape of phase III trials that are ongoing, and look to the future of immune checkpoint blockade as a potential curative therapy for surgically resectable lung cancer.
引用
收藏
页码:543 / 547
页数:5
相关论文
共 50 条
  • [1] Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer
    Hindie, Elif
    [J]. LANCET, 2024, 404 (10449): : 241 - 241
  • [2] What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
    Cameron, Robert B.
    Hines, Jacobi B.
    Torri, Valter
    Porcu, Luca
    Donington, Jessica
    Bestvina, Christine M.
    Vokes, Everett
    Dolezal, James M.
    Esposito, Alessandra
    Garassino, Marina C.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [3] Perioperative Immunotherapy - A KEY toward Improved Outcomes for Early-Stage Lung Cancer?
    Lovly, Christine M. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (06): : 560 - 561
  • [4] Treatment of Early-Stage Lung Cancer
    Timmerman, Robert D.
    Fernando, Hiran C.
    [J]. CANCER JOURNAL, 2011, 17 (01): : 1 - 2
  • [5] Stigma in Early-Stage Lung Cancer
    Bedard, Sarah
    Sasewich, Hannah
    Culling, Jessica
    Turner, Simon R.
    Pellizzari, Janelle
    Johnson, Scott
    Bedard, Eric L. R.
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2022, 56 (12) : 1272 - 1283
  • [6] Immunotherapy for early-stage non-small cell lung cancer: A system review
    Gao, Jingyi
    Zhang, Chao
    Wei, Zhigang
    Ye, Xin
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (04) : 849 - 865
  • [7] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [8] Multigene predictors in early-stage breast cancer: moving in or moving out?
    Ross, Jeffrey S.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (02) : 129 - 135
  • [9] Limited Resection for Early-Stage Lung Cancer
    Tarek Mekhail
    Joseph Boyer
    [J]. Current Oncology Reports, 2010, 12 : 285 - 287
  • [10] Cryoablation of Early-Stage Primary Lung Cancer
    Inoue, Masanori
    Nakatsuka, Seishi
    Jinzaki, Masahiro
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014